Anke L Stuurman
Biographic Data
| ID | 7782086 |
|---|---|
| NAME | Anke L Stuurman |
| GIVEN NAMES | Anke L |
| FAMILY NAME | Stuurman |
| SIGNATURE | STUURMAN A L |
| AFFILIATIONS | National Institute for Public Health and the Environment |
| ORCID | 0000-0002-4157-1315 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe
Introduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017-2018 to its final season in 2021-20…
Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the Covid-19 Emergence
The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public-private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to wor…
Measuring underreporting and under-ascertainment in infectious disease datasets
When routine data are used to make decisions on resource allocation or to estimate epidemiological parameters in populations, it becomes important to understand when, where and to what extent these data represent the true picture of disease, and in some instances (such as priority setting) it is necessary to adjust for underestimation. MFs can be used to adjust notification and surveillance data to provide more realistic estimates of incidence
No prominent works on this page.
Measuring underreporting and under-ascertainment in infectious disease datasets
When routine data are used to make decisions on resource allocation or to estimate epidemiological parameters in populations, it becomes important to understand when, where and to what extent these data represent the true picture of disease, and in some instances (such as priority setting) it is necessary to adjust for underestimation. MFs can be used to adjust notification and surveillance data to provide more realistic estimates of incidence
Challenges and Adaptation of a European Influenza Vaccine Effectiveness Study Platform in Response to the Covid-19 Emergence
The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) project is a public-private partnership aiming to build capacity in Europe for yearly estimation of brand-specific influenza vaccine effectiveness (IVE). DRIVE is a five-year project funded by IMI (Innovative Medicines Initiative). It was initiated as a response to the guidance on influenza vaccines by EMA (European Medicines Agency), which advised vaccine manufacturers to wor…
Brand-specific estimates of influenza vaccine effectiveness for the 2021–2022 season in Europe
Introduction: Development of Robust and Innovative Vaccine Effectiveness (DRIVE) was a European public-private partnership (PPP) that aimed to provide annual, brand-specific estimates of influenza vaccine effectiveness (IVE) for regulatory and public health purposes. DRIVE was launched in 2017 under the umbrella of the Innovative Medicines Initiative (IMI) and conducted IVE studies from its pilot season in 2017-2018 to its final season in 2021-20…
Medicine (3 works) · Public health (3 works) · Disease (2 works) · Environmental health (2 works) · Infectious disease (medical specialty (2 works) · Influenza vaccine (2 works) · Influenza Virus Research Studies (2 works) · Nursing (2 works) · Vaccination (2 works) · Vaccine Coverage and Hesitancy (2 works)